November 2021

Made in Italy: ‘beIT’ campaign to promote Italy at 360° kicks off

ROME, Nov. 30, 2021 (GLOBE NEWSWIRE) — (LaPresse) – An extraordinary communication campaign to promote Made in Italy, entitled ‘Italy is simply extraordinary: beIT’, has been successfully launched. The campaign, launched by the Italian Ministry of Foreign Affairs and International Cooperation in collaboration with the Italian Trade Agency (ICE), will

>

Bitdeer Group Contributes to Local Communities in Wyoming and Texas

Bitdeer Group gives back to the communities of Wyoming and Rockdale, Texas Bitdeer Group Contributes to Local Communities in Wyoming and Texas SINGAPORE, Nov. 30, 2021 (GLOBE NEWSWIRE) — Bitdeer Group provides digital asset mining services to individual and institutional clients around the world, and has set up branches in

>

CNH Industrial completes the acquisition of Raven Industries

London, November 30, 2021 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announced that it has completed its acquisition of Raven Industries, Inc., a U.S.-based leader in precision agriculture technology. The acquisition builds upon a long partnership and is an important milestone in CNH Industrial’s digital transformation. “Raven is

>

Eagle Eye Networks Forecasts Key Video Surveillance Trends for 2022

Businesses are turning to video surveillance to help them adapt and thrive amidst sustained disruptions and changes in the business environment 2022 Trends in Video Surveillance Report Released Today AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) — Eagle Eye Networks, the global leader in cloud video surveillance, today released the

>

Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

4th approved indication for toripalimab SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products Administration (NMPA) of China has approved its supplemental New Drug Application (sNDA) for toripalimab in combination with cisplatin and

>